A comprehensive review of erectile dysfunction in men with diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 3, 2015, Pages 141-158

  Kamenov, Z A ^a,b  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

diabetes; diabetic neuropathy; erectile dysfunction; intracavernosal injection; PDE 5 inhibitor; penile implant

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AVANAFIL; CALCIUM CHANNEL; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLATE CYCLASE; MIRODENAFIL; MYOSIN LIGHT CHAIN; NERVE GROWTH FACTOR; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; POLYOL; PROTEIN KINASE C; RHO KINASE; SILDENAFIL; TADALAFIL; UDENAFIL; VARDENAFIL; VASOACTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGING; ANDROGEN THERAPY; ARTERIAL PRESSURE; ARTERY DISEASE; BALANITIS; BIOAVAILABILITY; CALCIUM CELL LEVEL; CORPUS CAVERNOSUM; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGONADISM; LIFE EXPECTANCY; MALE; MALE SEXUAL DYSFUNCTION; METABOLIC REGULATION; MULTICENTER STUDY (TOPIC); MUSCLE ATROPHY; OXIDATIVE STRESS; PANDEMIC; PATIENT SATISFACTION; PENIS PROSTHESIS; PEYRONIE DISEASE; PHARMACEUTICAL CARE; PHIMOSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SMOOTH MUSCLE; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; VASCULAR SURGERY; VEIN BLOOD FLOW; VEIN OCCLUSION; DIABETES COMPLICATIONS;

DIABETES COMPLICATIONS; ERECTILE DYSFUNCTION; HUMANS; MALE;

EID: 84925255664     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1394383     Document Type: Review

References (181)

1. Aaberg M. L., Burch D. M., Hud Z. R. et al. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications: 2008; 22 83 87
2. th IDF World Congress, 18-22.10.2009, Montreal, Canada; P-1370, Book of abstracts p.462
3. Al-Amran F. G., Zwain A. A., Hadi N. R. et al. Autonomic cerebral vascular response to sildenafil in diabetic patient. Diabetol Metab Syndr: 2012; 27; 4 2
4. Angelopoulos N., Papanikolaou G., Noutsou M. et al. Glucose Metabolism, Insulin Secretion and Insulin Sensitivity in Juvenile Hemochromatosis. A Case Report and Review of the Literature. Exp Clin Endocrinol Diabetes: 2007; 115 192 197
5. Angulo J., González-Corrochano R., Cuevas P. et al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med: 2010; 7 2 Pt 1 758 768
6. Arafa M., Eid H., El-Badry A. et al. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res: 2007; 19 213 217
7. Avasthi A., Grover S., Bhansali A. et al. Erectile dysfunction in diabetes mellitus contributes to poor quality of life. Int Rev Psychiatry: 2011; 23 93 99
8. Baba K., Yajima M., Carrier S. et al. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology: 2000; 56 533 538
9. Bacon C. G., Hu F. B., Giovannucci E. et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care: 2002; 25 1458
10. Bartolini M., Giommi R., Forti G. et al. Organic, relational and psychological factors in erectiledys function in men with diabetes mellitus. Eur Urol: 2004; 46 222 228
11. Basu A., Ryder R. E. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs: 2004; 64 2667 2688
12. Belkoff L. H., McCullough A., Goldstein I. et al. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract: 2013; 67 333 341
13. Berardis G. D., Franciosi M., Belfigli M. et al. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care: 2002; 25 284 291
14. Bivalacqua T. J., Champion H. C., Usta M. F. et al. RhoA/Rhokinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA: 2004; 101 9121 9126
15. Bivalacqua T. J., Usta M. F., Champion H. C. et al. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl: 2003; 24 06 S17 S37
16. Bivalacqua T. J., Usta M. F., Kendirci M. et al. Superoxide anion production in the rat penis impairs EF in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med: 2005; 2 187 197
17. Boulton A. J., Kempler P., Ametov A. et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev: 2013; 29 327 333
18. Brock G., Nehra A., Lipshultz L. I. et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol: 2003; 170 4, pt 1 1278 1283
19. Brock G. B., McMahon C. G., Chen K. K. et al. Efficacy and safety of tadalafi l for the treatment of erectile dysfunction: results of integrated analyses. J Urol: 2002; 168 1332 1336
20. Bucala R., Tracey K. J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest: 1991; 87 432 438
21. Burchardt T., Burchardt M., Karden J. et al. Reduction of endothelial and smooth muscle density in the corpora cavernosa of the streptozotocin induced diabetic rat. J Urol: 2000; 164 1807 1811
22. Burke F. P., Jacobson D. F., McGree M. E. et al. Diabetes and sexual dysfunction in Olmsted County, Minnesota. J Sex Med: 2006; 3 01 19
23. Burke J. P., Jacobson D. J., McGree M. E. et al. Diabetes and sexual dysfunction: Result from Olmsted county study of urinary symptoms and health status among men. The journal of urology: 2007; 177 1438 1442
24. Burke R. M., Evans J. D. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag: 2012; 8 517 523
25. Burnett A. L., Strong T. D., Trock B. J. et al. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol: 2009; 181 245 251
26. Buvat J., van Ahlen H., Schmitt H. et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med: 2006; 3 512 520
27. Buyukafsar K., Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol: 2003; 472 235 238
28. Carson C. C. 3rd, Mulcahy J. J., Harsch M. R. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of follow-up. J Urol: 2011; 185 614 618
29. Carson C. C., Rajfer J., Eardley I. et al. The efficacy and safety of tadalafi l: an update. BJU Int: 2004; 93 1276 1281
30. Carson C. C., Shabsigh R., Segal S. et al. Efficacy, safety, and treatment satisfaction of tadalafi l versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology: 2005; 65 353 359
31. Cartledge J. J., Eardley I., Morrison J. F. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. B J U Int: 2001; 87 402 407
32. Chitaley K., Kupelian V., Subak L. et al. Diabetes, obesity and erectile dysfunction: field overview and research priorities. J Urol: 2009; 182 6 Suppl S45 S50
33. Chitaley K. Type 1 and type 2 diabetic-erectile dysfunction: same diagnosis (ICD-9), different disease? J Sex Med: 2009; 6 suppl 262
34. Christ G. J., Lerner S. E., Kim D. C. et al. Endothelin-1 as a putative modulator of erectile dysfunction: I. Characteristics of contraction of isolated corporal tissue strips. J Urol: 1995; 153 1998 2003
35. Chrysant S. G. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep: 2013; 15 475 483
36. Chua R., Tar M., Melman A. et al. Streptozotocin-induced diabetes results in time-dependent upregulation of the endothelin/rho-kinase pathway in rat corpus cavernosum smooth muscle. J Sex Med: 2006; 3 01 25
37. Chung E., Van C. T., Wilson I. et al. Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol: 2013; 31 591 595
38. Clozel M., Gray G. A., Breu V. et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun: 1992; 186 867 873
39. Coombs P. G., Heck M., Guhring P. et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int: 2012; 110 1787 1791
40. Corona G., Giorda C. B., Cucinotta D. et al. Gruppo di studio SUBITODE Sexual dysfunction at the onset of type 2 diabetes: The interplay of depression, hormonal and cardiovascular factors. J Sex Med: 2014; 11 2065 2073
41. Corona G., Mannucci E., Petrone L. et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med: 2007; 4 1038 1045
42. Corrales J. J., Burgo R. M., Garca-Berrocal B. et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism: 2004; 53 666 672
43. Dean J., Hackett G. I., Gentile V. et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med: 2006; 3 650 661
44. Deyoung L., Chung E., Kovac J. R. et al. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl: 2012; 33 176 180
45. Diemont W., Meuleman E. Neurological testing in erectile dysfunction. J Androl: 1997; 18 345 350
46. Dimmeler S., Zeiher A. M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circulation Research: 2000; 87 434 439
47. Drivsholm T., de Fine Olivarius N., Nielsen A. B. et al. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia: 2005; 48 210 214
48. Dyck P. J., Kratz K. M., Karnes J. L. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology: 1993; 43 817 824
49. Eardley I., Fisher W., Rosen R. C. et al. The multinational Men's Attitudes to Life Events and Sexuality study: the influence of diabetes on self-reported erectile function, attitudes and treatment-seeking patterns in men with erectile dysfunction. Int J Clin Pract: 2007; 61 1446 1453
50. Eardley I., Rosen R., Fisher W. A. et al. Attitudes toward treatment of erectile dysfunction: results from the MALES study. Eur Urol Suppl: 2003; 2 97 Abstract 377
51. Eid J. F., Wilson S. K., Cleves M. et al. Coated implants and no touch surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology: 2012; 79 1310 1315
52. El-Sakka A. I., Tayeb K. A. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol: 2005; 174 1026 1030
53. Fakjian N., Hunter S., Cole G. W. et al. An argument for circumcision.Prevention of balanitis in the adult. Arch Dermatol: 1990; 126 1046 1047
54. Fedele D., Coscelli C., Santeusanio F. et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care: 1998; 21 1973 1977
55. Feldman H. A., Goldstein I., Hatzichristou D. G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol: 1994; 151 54 61
56. Frokjær J. B., Brock C., Softeland E. et al. Macrostructural Brain Changes in Patients with Longstanding Type 1 Diabetes Mellitus - a Cortical Thickness Analysis Study. Exp Clin Endocrinol Diabetes: 2013; 121 354 360
57. Fonseca V., Seftel A., Denne J. et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia: 2004; 47 1914 1923
58. Gareri P., Castagna A., Francomano D. et al. Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. Int J Endocrinol: 2014; 17 Article ID 878670 15 pages
59. Giagulli V. A., Moghetti P., Kaufman J. M. et al. Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets: 2013; 13 125 134
60. Giugliano F., Maiorino M. I., Bellastella G. et al. Adherence to Mediterranean diet and erectile dysfunction in men with type 2 Diabetes. J Sex Med: 2010; 7 1911 1917
61. Gluckman E. Hemochromatosis in heterozygotes. N Engl J Med: 1996; 24 1837 1838
62. Goldstein I., Young J. M., Fischer J. et al. Vardenafil Diabetes Study Group Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care: 2003; 26 777 783
63. Goldstein I., Jones L. A., Belkoff L. H. et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc: 2012; 87 843 852
64. Grover-Páez F., Villegas Rivera G., Guillén Ortíz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract: 2007; 78 136 140
65. Hakim L. S., Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am: 1996; 25 379 400
66. Hatzichristou D., Montorsi F., Buvat J. et al. European Vardenafil Study Group The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol: 2004; 45 634 641
67. Hatzimouratidis K., Hatzichristou D. G. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs: 2005; 65 1621 1650
68. Hecht M. J., Neundorfer B., Kiesewetter F. et al. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res: 2001; 23 651 654
69. Hellstrom W. J., Gittelman M., Karlin G. et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, doubleblind, placebo-controlled trial. J Androl: 2002; 23 763 771
70. Hidalgo-Tamola J., Chitaley K. Type 2 diabetes mellitus and erectile dysfunction. J Sex Med: 2009; 6 916 926
71. Hidmark A., Fleming T., Vittas S. et al. A New Paradigm to Understand and Treat Diabetic Neuropathy. Exp Clin Endocrinol Diabetes: 2014; 122 201 207
72. Incrocci L., Slob A. K., Hop W. C. Tadalafi l (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology: 2007; 70 1190 1193
73. th edition: 2013
74. Jarow J. P. Risk factors for penile prosthetic infection. J Urol: 1996; 156 2 Pt 1 402 404
75. Jesmin S., Sakuma I., Salah-Eldin A. et al. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol: 2003; 31 401 418
76. Jevtich M. J., Khawand N. Y., Vidic B. Clinical significance of ultrastructural findings in the corpora cavernosa of normal and impotent men. J Urol: 1990; 143 289 293
77. Johannes C. B., Araujo A. B., Feldman H. A. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol: 2000; 163 460
78. Kadioglu A., Oktar T., Kandirali E. et al. Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res: 2004; 16 540 543
79. Kamenov Z., Christov V., Yankova T. Erectile dysfunction in diabetic men - linked more to microangiopathic complications and neuropathy than to macroangiopathic disturbances. Journal of Men's Health and Gender: 2007; 4 64 73
80. Kamenov Z., Higashino H., Todorova M. et al. Physiological characteristics of diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Methods Find Exp Clin Pharmacol: 2006; 28 13 18
81. Kamenov Z. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. JSM: 2011; 8 851 864
82. Kamenov Z. Erectile dysfunction in diabetic men. In: Sexual dysfunctions. Risk factors, psychological impact, and treatment. (ed.). Frederique Courtois Nova Science Publishers, Inc. New York: 2013; ISBN: 978-1-62808-768-0
83. Kamenov Z. A., Parapunova R. A., Georgieva R. T. Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus. Gend Med: 2010; 7 600 615
84. Kamenov Z. A., Petrova J. J., Christov V. G. Diagnosis of diabetic neuropathy using simple somatic and a new autonomic (neuropad) tests in the clinical practice. Exp Clin Endocrinol Diabetes: 2010; 118 226 233
85. Kamenov Z. A., Traykov L. D. Diabetic autonomic neuropathy. Adv Exp Med Biol: 2012; 771 176 193
86. Kamenov Z. A., Traykov L. D. Diabetic somatic neuropathy. Adv Exp Med Biol: 2012; 771 155 175
87. Kang S. G., Kim J. J. Udenafil: efficacy and tolerability in the management of erectile dysfunction. Ther Adv Urol: 2013; 5 101 110
88. Kawano K., Hirashima T., Mori S. et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes: 1992; 41 1422 1428
89. Khan M. A., Thompson C. S., Jeremy J. Y. et al. The effect of superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int: 2001; 87 98 103
90. Klein R., Klein B. E., Moss S. E. Ten-year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes. J Diabetes Compl: 2005; 19 35
91. Levine L. A., Dimitriou R. J. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am: 2001; 28 335 341
92. Lewis R. W. Epidemiology of erectile dysfunction. Urol Clin North Am: 2001; 28 209 216
93. Lin C-S, Ho H-C, Chen K-C et al. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU International: 2002; 89 955 960
94. Lu C-C, Jiann B-P, Sun C-C et al. Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. J Sex Med: 2009; 6 1719 1728
95. Lu Y. L., Shen Z. J., Wang H. et al. Ultrastructural changes of penile tunica albuginea in diabetic rats. Asian J Androl: 2004; 6 365 368
96. Malavige L. S., Levy J. C. Erectile dysfunction in diabetes mellitus. J Sex Med: 2009; 6 1232 1247
97. Malavige L. S., Jayaratne S. D., Kathriarachchi S. T. et al. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med: 2008; 5 2125 2134
98. Manes C., Papanas N., Exiara T. et al. The Indicator Test Neuropad in the Assessment of Small and Overall Nerve Fibre Dysfunction in Patients with Type 2 Diabetes: a Large Multicentre Study. Exp Clin Endocrinol Diabetes: 2014; 122 195 199
99. Martin-Morales A., Sanchez-Cruz J. J., Saenz de Tejada I. et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol: 2001; 166 569 574
100. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med: 2004; 1 292 300
101. Meuleman E. J., Eardley I., Rosen R. et al. Attitudes toward treatment of erectile dysfunction: results from the MALES (Men's Attitudes toward Life Events and Sexuality) study. Presented at: Annual Meeting of the Asian Pacific Society of Sexual and Impotence Research; Cebu, Philippines: 2003
102. Ming X. F., Viswambharan H., Barandier C. et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol: 2002; 22 8467 8477
103. Montague D. K., Angermeier K. W., Lakin M. M. Penile prosthesis infections. Int J Impot Res: 2001; 13 326 328
104. Montorsi F., Hellstrom W. J., Valiquette L. et al. North American and European Vardenafil Groups Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology: 2004; 64 1187 1195
105. Montorsi P., Montorsi F., Schulman C. C. Is erectile dysfunction the tip of the iceberg of a systemic vascular disorder? Eur Urol: 2003; 44 352 354
106. Moon du G., Yang D. Y., Lee C. H. et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med: 2011; 8 2048 2061
107. Moore C. R., Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl: 2006; 8 675 684
108. Mulligan T., Frick M. F., Zuraw Q. C. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract: 2006; 60 762 769
109. Musicki B., Palese M. A., Crone J. K. et al. Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection. Biol Reprod: 2004; 70 282 289
110. National Intelligence Council Global trends 2025: A Transformed World: 2008
111. Ng K. K., Lim H. C., Ng F. C. et al. The use of sildenafil in patients with erectile dysfunction in relation to diabetes mellitus - a study of 1,511 patients. Singapore Med J: 2002; 43 387 390
112. Nieschlag E., Swerdloff R., Behre H. M. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl: 2006; 27 135 137
113. Nofzinger E. A. Sexual Dysfunction in Patients with Diabetes Mellitus: The Role of a Central Neuropathy. Semin Clin Neuropsychiatry: 1997; 2 31 39
114. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol: 2003; 92 19M 25M
115. Papapetropoulos A., García-Cardeña G., Madri J. A. et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. Journal of Clinical Investigation: 1997; 100 3131 3139
116. Park H. J., Choi H. K., Ahn T. Y. et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med: 2010; 7 2842 2850
117. Park J. K., Lee S. O., Kim Y. G. et al. Role of rho-kinase activity in angiotensin II-induced contraction of rabbit clitoral cavernosum smooth muscle. Int J Impot Res: 2002; 14 472 477
118. Park S. H., Park S. W., Cha B. Y. et al. Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. Asian J Androl: 2014
119. Penson D. F., Latini D. M., Lubeck D. P. et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care: 2003; 26 1093 1099
120. Phé V., Rouprêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab: 2012; 38 1 13
121. Porst H., Oelke M., Goldfischer E. R. et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology: 2013; 82 667 673
122. Porst H., Rajfer J., Casabu A. et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med: 2008; 5 2160 2169
123. Porst H., Rosen R., Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res: 2001; 13 192 199
124. st edition. Oxford Blackwell: 2007
125. Potempa A. J., Ulbrich E., Bernard I. et al. Vardenafil Study Group Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. Eur Urol: 2004; 46 73 79
126. Price D., Hackett G. Management of erectile dysfunction in diabetes: an update for 2008. Curr Diab Rep: 2008; 8 437 443
127. Price D. E., Cooksey G., Jehu D. et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med: 1991; 8 964 967
128. Redrow G. P., Thompson C. M., Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. Expert Opin Pharmacother: 2014; 15 1827 1836
129. Rees R. W., Ziessen T., Ralph D. J. et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res: 2002; 14 1 7
130. Reinhardt W., Darwiche K., Wiemann J. et al. Sleep apnoe syndrome is associated with low serum testosterone levels and reversible by cpap- treatment. Exp Clin Endocrinol Diabetes: 2004; 112-P12
131. Rendell M. S., Rajfer J., Wicker P. A. et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA: 1999; 281 421 426
132. Rhoden E. L., Teloken C., Ting H. Y. et al. Prevalence of Peyronie's disease in men over 50-year-old from Southern Brazil. Int J Impot Res: 2001; 13 291 293
133. Rosen R. C., Riley A., Wagner G. et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile function. Urology: 1997; 49 822 830
134. Ryan J. G. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gender Medicine: 2009; 6 86 108
135. Ryu J. K., Cho K. S., Kim S. J. et al. Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. World J Mens Health: 2013; 31 83 102
136. Saenz de Tejada I., Anglin G., Knight J. R. et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care: 2002; 25 2159 2164
137. Saenz de Tejada I., Emmick J., Anglin G. et al. The effect of IC351 taken as needed for treatment of erectile dysfunction in men with diabetes. Eur Urol: 2001; 39 16 abs.55
138. Safarinejad M. R. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications: 2004; 18 205 210
139. Schulman C. C., Shen W., Stothard D. R. et al. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology: 2004; 64 783 788
140. Schwarzer U., Sommer F., Klotz T. et al. The prevalence of Peyronie's disease: Results of a large survey. BJU Int: 2001; 88 727 730
141. Seftel A. D., Vaziri N. D., Ni Z. et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology: 1997; 50 1016 1026
142. Segal R. L., Camper S. B., Ma L. et al. Prediction model for penile prosthesis implantation for erectile dysfunction management. Curr Med Res Opin: 2014; 1 1 7
143. Selvarajah D., Wilkinson I. D., Maxwell M. et al. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy. Diabetes Care: 2014; 37 1681 1688
144. Sheehy A. M., Phung Y. T., Riemer R. K. et al. Growth factor induction of nitric oxide synthase in rat pheochromocytoma cells. Molecular Brain Research: 1997; 52 71 77
145. Siddiqui M. A., Ahmed Z., Khan A. A. Psychological Impact on Sexual Health among Diabetic Patients: A Review. International Journal of Diabetes Research: 2012; 1 28 31
146. Sidi A. A., Becher E. F., Zhang G. et al. Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol: 1990; 144 1154 1156
147. Siemons L. J., Mahler C. H. Hypogonadotrophic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J Clin Endocrinol Metab: 1987; 65 585 587
148. Sima AA F., Ristic H., Merry A. et al. The primary preventional and secondary interventative effects of acetyl-L-carnitine on diabetic neuropathy in the BB/W-rat. J Clin Invest: 1996; 97 1900 1907
149. Singh R., Barden A., Mori T. et al. Advanced glycation end-products: a review. Diabetologia: 2001; 44 129 146
150. Smith A. D. Causes and classification of impotence. Urol Clin North Am: 1981; 8 79 89
151. Song W. D., Yuan Y. M., Cui W. S. et al. Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. Asian J Androl: 2013; 15 658 661
152. Stoian D. I., Craciunescu M., Anastasiu D. D. et al. Sustained life style changes - impact on sexual quality, metabolic parameters and QoL in overweight men with metabolic syndrome. Exp Clin Endocrinol Diabetes: 2014; 122-P172
153. Stracke H., Gaus W., Achenbach U. et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes: 2008; 116 600 605
154. Stuckey B. G., Jadzinsky M. N., Murphy L. J. et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care: 2003; 26 279 284
155. Sun L., Peng F. L., Yu Z. L. et al. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol: 2014
156. Teerlink J. R., Breu V., Sprecher U. et al. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res: 1994; 74 105 114
157. Tefekli A., Kandirali E., Erol B. et al. Peyronie's disease: A silent consequence of diabetes mellitus. Asian J Androl: 2006; 8 75 79
158. Tesfaye S., Stevens L. K., Stephenson J. M. et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia: 1996; 39 1377 1384
159. Traish A., Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med: 2005; 2 759 770
160. Tsertsvadze A., Fink H. A., Yazdi F. et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med: 2009; 151 650 661
161. Usta M. F., Bivalacqua T. J., Yang D. Y. et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol: 2003; 170 1437 1442
162. Valiquette L., Young J. M., Moncada I. et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc: 2005; 80 1291 1297
163. Vardi M., Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev: 2007; 24 CD002187
164. Vardi Y., Sprecher E., Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol: 2000; 163 467 470
165. Vickers M. A., Wright E. A. Erectile dysfunction in the patient with diabetes mellitus. Am J Manag Care: 2004; 10 1 Suppl S3 S11
166. Vinik A., Richardson D. Erectile dysfunction in diabetes. Diabetes Rev: 1998; 6 16 33
167. Vinik A. I., Holland M. T., Le Beau J. M. et al. Diabetic neuropathies. Diabetes Care: 1992; 15 1926 1975
168. Wallis R. M., Corbin J. D., Francis S. H. et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol: 1999; 83 3C 12C
169. Walsh T. J., Hotaling J. M., Smith A. et al. Men with diabetes may require more aggressive treatment for erectile dysfunction. Int J Impot Res: 2014; 26 112 115
170. Wang C., Nieschlag E., Swerdloff R. et al. International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl: 2009; 30 1 9
171. Wang H., Eto M., Steers W. D. et al. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem: 2002; 277 30614 30621
172. Wilkinson I. D., Selvarajah D., Greig M. et al. Magnetic resonance imaging of the central nervous system in diabetic neuropathy. Curr Diab Rep: 2013; 13 509 516
173. Wilson S. K., Carson C. C., Cleves M. A. et al. Quantifying risk of penile prosthesis infection with elevated glycosylated haemoglobin. J Urol: 1998; 159 1537 1539 [discussion 1539-1540]
174. Wilson S. K., Delk J. R. 2nd. Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol: 1995; 153 3 Pt 1 659 661
175. Wing R. R., Rosen R. C., Fava J. L. et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the look AHEAD trial. J Sex Med: 2010; 7 156 165
176. Yagihashi S., Yamagishi S., Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res Clin Pract: 2007; 77 1 suppl S184 S189
177. Yan S. F., Ramasamy R., Schmidt A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab: 2008; 4 285 293
178. Yilmaz D., Bayatli N., Un O. et al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology: 2014; 83 508
179. Young M. J., Boulton AJ M., McLeod A. F. et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population. Diabetologia: 1993; 36 150 156
180. Zargaroff S., Sharma V., Berhanu D. et al. National trends in the treatment of penile prosthesis infections by explantation alone vs. immediate salvage and reimplantation. J Sex Med: 2014; 11 1078 1085
181. Ziegler D. Treatment of diabetic polyneuropathy: Update 2006. Ann N Y Acad Sci: 2006; 1084 250 266